Prognostic value of circulating lymphocyte subsets in primary central nervous system lymphoma View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2022-06-28

AUTHORS

Axel Berthelot, Celine Bequet, Vincent Harlay, Gregorio Petrirena, Chantal Campello, Maryline Barrié, Romain Appay, Olivier Chinot, Emeline Tabouret

ABSTRACT

BackgroundImmunity plays an important role in CNS-DLBCL development. CNS-DLBCL predictive factors need to be improved.ObjectiveTo evaluate the predictive value of circulating lymphocyte subsets in PCNSL patients.MethodsWe prospectively analyzed blood lymphocyte immunophenotyping (LIP) in newly CNS-DLBCL referred to our institution between December 2013 and January 2020. LIP analysis was performed before rituximab and chemotherapy administration. The clinical, radiological, histological, biological and treatment data were retrospectively collected.ResultsFifty-three patients were included with a median age of 69.7 (range 21.7–87.5). Median KPS was 60 (range 30–100). Thirty-three patients (64%) presented with one or several lymphopenias: 21 (40%), 24 (46%) and 9 (17%) NK, T and B lymphopenias respectively. Only 11 patients (21%) had normal LIP. Median CD4+/CD8+ ratio was 2.11 (range 0.54–9.11). This ratio was normal, low or high in 27%, 28% and 44% of patients respectively. The presence of steroids did not impact LIP results. Complete, partial responses, stable and progressive disease (PD) were observed in 24 (50%), 10 (21%), 4 (8%), and 10 (21%) patients respectively. CD4+/CD8+ ratio tended to be different between refractory (PD patients) and non-refractory patients (p = 0.077, ROC AUC: 0.684). Median progression-free survival (PFS) and overall survival (OS) were 14.7 (95%CI 6.5–22.9) and 43.2 (95%CI 21.6–64.9) months, respectively. In multivariate analyses, adjusted by KPS, a CD4+/CD8+ ratio > 1.97 was associated with poor PFS [p = 0.043, HR = 3.32 (1.02–4.88)] and tended to be associated with worse OS (p = 0.064).ConclusionLIP at baseline may predict refractory disease and exhibits a prognostic value in CNS-DLBCL patients. More... »

PAGES

15-22

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s11060-022-04032-5

DOI

http://dx.doi.org/10.1007/s11060-022-04032-5

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1149025622

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/35763119


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1109", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Neurosciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Central Nervous System", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lymphocyte Count", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lymphocyte Subsets", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lymphoma, Large B-Cell, Diffuse", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lymphopenia", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prognosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Rituximab", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "APHM, CHU Timone, Service de Neurooncologie, Marseille, France", 
          "id": "http://www.grid.ac/institutes/grid.411266.6", 
          "name": [
            "APHM, CHU Timone, Service de Neurooncologie, Marseille, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Berthelot", 
        "givenName": "Axel", 
        "id": "sg:person.013514371275.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013514371275.39"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "APHM, CHU Timone, Service de Neurooncologie, Marseille, France", 
          "id": "http://www.grid.ac/institutes/grid.411266.6", 
          "name": [
            "APHM, CHU Timone, Service de Neurooncologie, Marseille, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bequet", 
        "givenName": "Celine", 
        "id": "sg:person.01366075341.14", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01366075341.14"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "APHM, CHU Timone, Service de Neurooncologie, Marseille, France", 
          "id": "http://www.grid.ac/institutes/grid.411266.6", 
          "name": [
            "APHM, CHU Timone, Service de Neurooncologie, Marseille, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Harlay", 
        "givenName": "Vincent", 
        "id": "sg:person.013546622047.13", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013546622047.13"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "APHM, CHU Timone, Service de Neurooncologie, Marseille, France", 
          "id": "http://www.grid.ac/institutes/grid.411266.6", 
          "name": [
            "APHM, CHU Timone, Service de Neurooncologie, Marseille, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Petrirena", 
        "givenName": "Gregorio", 
        "id": "sg:person.0721565704.73", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0721565704.73"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "APHM, CHU Timone, Service de Neurooncologie, Marseille, France", 
          "id": "http://www.grid.ac/institutes/grid.411266.6", 
          "name": [
            "APHM, CHU Timone, Service de Neurooncologie, Marseille, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Campello", 
        "givenName": "Chantal", 
        "id": "sg:person.0646537516.22", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0646537516.22"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "APHM, CHU Timone, Service de Neurooncologie, Marseille, France", 
          "id": "http://www.grid.ac/institutes/grid.411266.6", 
          "name": [
            "APHM, CHU Timone, Service de Neurooncologie, Marseille, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Barri\u00e9", 
        "givenName": "Maryline", 
        "id": "sg:person.01012432765.90", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01012432765.90"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "APHM, CHU Timone, Service d\u2019anatomopathologie, Marseille, France", 
          "id": "http://www.grid.ac/institutes/grid.411266.6", 
          "name": [
            "Aix-Marseille Univ, CNRS, INP, Inst Neurophysiopathol, Marseille, France", 
            "APHM, CHU Timone, Service d\u2019anatomopathologie, Marseille, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Appay", 
        "givenName": "Romain", 
        "id": "sg:person.011205067533.95", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011205067533.95"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Aix-Marseille Univ, CNRS, INP, Inst Neurophysiopathol, Marseille, France", 
          "id": "http://www.grid.ac/institutes/grid.464051.2", 
          "name": [
            "APHM, CHU Timone, Service de Neurooncologie, Marseille, France", 
            "Aix-Marseille Univ, CNRS, INP, Inst Neurophysiopathol, Marseille, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chinot", 
        "givenName": "Olivier", 
        "id": "sg:person.0704465355.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0704465355.32"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Neuro-Oncology Department, University Hospital La Timone, 264 rue Saint Pierre, 13005, Marseille, France", 
          "id": "http://www.grid.ac/institutes/grid.411266.6", 
          "name": [
            "APHM, CHU Timone, Service de Neurooncologie, Marseille, France", 
            "Aix-Marseille Univ, CNRS, INP, Inst Neurophysiopathol, Marseille, France", 
            "Neuro-Oncology Department, University Hospital La Timone, 264 rue Saint Pierre, 13005, Marseille, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tabouret", 
        "givenName": "Emeline", 
        "id": "sg:person.01160514623.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01160514623.82"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s11060-007-9397-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052553767", 
          "https://doi.org/10.1007/s11060-007-9397-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00277-021-04474-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1135850698", 
          "https://doi.org/10.1007/s00277-021-04474-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00262-020-02575-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1127141873", 
          "https://doi.org/10.1007/s00262-020-02575-y"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2022-06-28", 
    "datePublishedReg": "2022-06-28", 
    "description": "BackgroundImmunity plays an important role in CNS-DLBCL development. CNS-DLBCL predictive factors need to be improved.ObjectiveTo evaluate the predictive value of circulating lymphocyte subsets in PCNSL patients.MethodsWe prospectively analyzed blood lymphocyte immunophenotyping (LIP) in newly CNS-DLBCL referred to our institution between December 2013 and January 2020. LIP analysis was performed before rituximab and chemotherapy administration. The clinical, radiological, histological, biological and treatment data were retrospectively collected.ResultsFifty-three patients were included with a median age of 69.7 (range 21.7\u201387.5). Median KPS was 60 (range 30\u2013100). Thirty-three patients (64%) presented with one or several lymphopenias: 21 (40%), 24 (46%) and 9 (17%) NK, T and B lymphopenias respectively. Only 11 patients (21%) had normal LIP. Median CD4+/CD8+\u2009ratio was 2.11 (range 0.54\u20139.11). This ratio was normal, low or high in 27%, 28% and 44% of patients respectively. The presence of steroids did not impact LIP results. Complete, partial responses, stable and progressive disease (PD) were observed in 24 (50%), 10 (21%), 4 (8%), and 10 (21%) patients respectively. CD4+/CD8+\u2009ratio tended to be different between refractory (PD patients) and non-refractory patients (p\u2009=\u20090.077, ROC AUC: 0.684). Median progression-free survival (PFS) and overall survival (OS) were 14.7 (95%CI 6.5\u201322.9) and 43.2 (95%CI 21.6\u201364.9) months, respectively. In multivariate analyses, adjusted by KPS, a CD4+/CD8+\u2009ratio\u2009>\u20091.97 was associated with poor PFS [p\u2009=\u20090.043, HR\u2009=\u20093.32 (1.02\u20134.88)] and tended to be associated with worse OS (p\u2009=\u20090.064).ConclusionLIP at baseline may predict refractory disease and exhibits a prognostic value in CNS-DLBCL patients.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s11060-022-04032-5", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094205", 
        "issn": [
          "0167-594X", 
          "1573-7373"
        ], 
        "name": "Journal of Neuro-Oncology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "159"
      }
    ], 
    "keywords": [
      "progression-free survival", 
      "overall survival", 
      "lymphocyte subsets", 
      "progressive disease", 
      "prognostic value", 
      "primary central nervous system lymphoma", 
      "median progression-free survival", 
      "poor progression-free survival", 
      "central nervous system lymphoma", 
      "ResultsFifty-three patients", 
      "worse overall survival", 
      "nervous system lymphoma", 
      "non-refractory patients", 
      "presence of steroids", 
      "median KPS", 
      "PCNSL patients", 
      "partial response", 
      "refractory disease", 
      "chemotherapy administration", 
      "median age", 
      "system lymphoma", 
      "predictive factors", 
      "CNS DLBCL", 
      "B lymphopenia", 
      "blood lymphocytes", 
      "normal lip", 
      "patients", 
      "predictive value", 
      "treatment data", 
      "multivariate analysis", 
      "lymphopenia", 
      "disease", 
      "survival", 
      "KPS", 
      "lip results", 
      "rituximab", 
      "lip analysis", 
      "lymphoma", 
      "lymphocytes", 
      "ObjectiveTo", 
      "steroids", 
      "MethodsWe", 
      "administration", 
      "NK", 
      "baseline", 
      "subset", 
      "months", 
      "important role", 
      "median", 
      "age", 
      "refractory", 
      "lip", 
      "response", 
      "ratio", 
      "factors", 
      "role", 
      "analysis", 
      "presence", 
      "values", 
      "data", 
      "institutions", 
      "development", 
      "results"
    ], 
    "name": "Prognostic value of circulating lymphocyte subsets in primary central nervous system lymphoma", 
    "pagination": "15-22", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1149025622"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s11060-022-04032-5"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "35763119"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s11060-022-04032-5", 
      "https://app.dimensions.ai/details/publication/pub.1149025622"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-09-02T16:08", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_951.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s11060-022-04032-5"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s11060-022-04032-5'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s11060-022-04032-5'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s11060-022-04032-5'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s11060-022-04032-5'


 

This table displays all metadata directly associated to this object as RDF triples.

241 TRIPLES      21 PREDICATES      101 URIs      90 LITERALS      17 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s11060-022-04032-5 schema:about N366e20b7787e4fbc9b355da20dfa3e96
2 N3bac3430133f41d88fb986a076f20997
3 N4b1011e955fe49d58c24907142422f9a
4 N4bb5e1078d1a4100b5304adc3f3d3df4
5 Na1c2633be6194e5b91582e045720114e
6 Naff6020c756d4583bd668371cf20e642
7 Nd09df8550e13431f8366563c6609acc1
8 Nef284a43ce024433b226b5047a9022d2
9 Nfdf0a39a7918460e93819e227366f8d2
10 Nfff13cda59964747adca067c9edfbbc0
11 anzsrc-for:11
12 anzsrc-for:1109
13 schema:author N512220e441de4bac9b8efbdc618a5b06
14 schema:citation sg:pub.10.1007/s00262-020-02575-y
15 sg:pub.10.1007/s00277-021-04474-3
16 sg:pub.10.1007/s11060-007-9397-0
17 schema:datePublished 2022-06-28
18 schema:datePublishedReg 2022-06-28
19 schema:description BackgroundImmunity plays an important role in CNS-DLBCL development. CNS-DLBCL predictive factors need to be improved.ObjectiveTo evaluate the predictive value of circulating lymphocyte subsets in PCNSL patients.MethodsWe prospectively analyzed blood lymphocyte immunophenotyping (LIP) in newly CNS-DLBCL referred to our institution between December 2013 and January 2020. LIP analysis was performed before rituximab and chemotherapy administration. The clinical, radiological, histological, biological and treatment data were retrospectively collected.ResultsFifty-three patients were included with a median age of 69.7 (range 21.7–87.5). Median KPS was 60 (range 30–100). Thirty-three patients (64%) presented with one or several lymphopenias: 21 (40%), 24 (46%) and 9 (17%) NK, T and B lymphopenias respectively. Only 11 patients (21%) had normal LIP. Median CD4+/CD8+ ratio was 2.11 (range 0.54–9.11). This ratio was normal, low or high in 27%, 28% and 44% of patients respectively. The presence of steroids did not impact LIP results. Complete, partial responses, stable and progressive disease (PD) were observed in 24 (50%), 10 (21%), 4 (8%), and 10 (21%) patients respectively. CD4+/CD8+ ratio tended to be different between refractory (PD patients) and non-refractory patients (p = 0.077, ROC AUC: 0.684). Median progression-free survival (PFS) and overall survival (OS) were 14.7 (95%CI 6.5–22.9) and 43.2 (95%CI 21.6–64.9) months, respectively. In multivariate analyses, adjusted by KPS, a CD4+/CD8+ ratio > 1.97 was associated with poor PFS [p = 0.043, HR = 3.32 (1.02–4.88)] and tended to be associated with worse OS (p = 0.064).ConclusionLIP at baseline may predict refractory disease and exhibits a prognostic value in CNS-DLBCL patients.
20 schema:genre article
21 schema:isAccessibleForFree false
22 schema:isPartOf Ncaa18c385e21416d916ebe9e8cf26b45
23 Nf538ee9083264af7bf59b9314dad7fdf
24 sg:journal.1094205
25 schema:keywords B lymphopenia
26 CNS DLBCL
27 KPS
28 MethodsWe
29 NK
30 ObjectiveTo
31 PCNSL patients
32 ResultsFifty-three patients
33 administration
34 age
35 analysis
36 baseline
37 blood lymphocytes
38 central nervous system lymphoma
39 chemotherapy administration
40 data
41 development
42 disease
43 factors
44 important role
45 institutions
46 lip
47 lip analysis
48 lip results
49 lymphocyte subsets
50 lymphocytes
51 lymphoma
52 lymphopenia
53 median
54 median KPS
55 median age
56 median progression-free survival
57 months
58 multivariate analysis
59 nervous system lymphoma
60 non-refractory patients
61 normal lip
62 overall survival
63 partial response
64 patients
65 poor progression-free survival
66 predictive factors
67 predictive value
68 presence
69 presence of steroids
70 primary central nervous system lymphoma
71 prognostic value
72 progression-free survival
73 progressive disease
74 ratio
75 refractory
76 refractory disease
77 response
78 results
79 rituximab
80 role
81 steroids
82 subset
83 survival
84 system lymphoma
85 treatment data
86 values
87 worse overall survival
88 schema:name Prognostic value of circulating lymphocyte subsets in primary central nervous system lymphoma
89 schema:pagination 15-22
90 schema:productId N965043db8e534799957ece4979705a3d
91 Na5cf3d0e518f479db72ba48b9ef34949
92 Nde5d32001242480aa9dc6e1478d13ea0
93 schema:sameAs https://app.dimensions.ai/details/publication/pub.1149025622
94 https://doi.org/10.1007/s11060-022-04032-5
95 schema:sdDatePublished 2022-09-02T16:08
96 schema:sdLicense https://scigraph.springernature.com/explorer/license/
97 schema:sdPublisher N3c10892dd374493cb7216b6a6a7b3228
98 schema:url https://doi.org/10.1007/s11060-022-04032-5
99 sgo:license sg:explorer/license/
100 sgo:sdDataset articles
101 rdf:type schema:ScholarlyArticle
102 N366e20b7787e4fbc9b355da20dfa3e96 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
103 schema:name Humans
104 rdf:type schema:DefinedTerm
105 N3bac3430133f41d88fb986a076f20997 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
106 schema:name Retrospective Studies
107 rdf:type schema:DefinedTerm
108 N3c10892dd374493cb7216b6a6a7b3228 schema:name Springer Nature - SN SciGraph project
109 rdf:type schema:Organization
110 N3cb088a6ec974ec7b0534f96e8f70c9e rdf:first sg:person.0721565704.73
111 rdf:rest N91f727121cd240e187504f311ce5b7e1
112 N4b1011e955fe49d58c24907142422f9a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Lymphoma, Large B-Cell, Diffuse
114 rdf:type schema:DefinedTerm
115 N4bb5e1078d1a4100b5304adc3f3d3df4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Prognosis
117 rdf:type schema:DefinedTerm
118 N512220e441de4bac9b8efbdc618a5b06 rdf:first sg:person.013514371275.39
119 rdf:rest N9228d245cdc043f0994cdaee9f84c73b
120 N6ac591dd39484959a76e32431378c304 rdf:first sg:person.01160514623.82
121 rdf:rest rdf:nil
122 N6b532166bf6e497192f6392cca39000f rdf:first sg:person.013546622047.13
123 rdf:rest N3cb088a6ec974ec7b0534f96e8f70c9e
124 N79090ada57364c3a8c15c30d54194ceb rdf:first sg:person.01012432765.90
125 rdf:rest Naff77926c0864d4bb3eb52fe48b14151
126 N875e8948b90a4cdab63b06a6b934be9b rdf:first sg:person.0704465355.32
127 rdf:rest N6ac591dd39484959a76e32431378c304
128 N91f727121cd240e187504f311ce5b7e1 rdf:first sg:person.0646537516.22
129 rdf:rest N79090ada57364c3a8c15c30d54194ceb
130 N9228d245cdc043f0994cdaee9f84c73b rdf:first sg:person.01366075341.14
131 rdf:rest N6b532166bf6e497192f6392cca39000f
132 N965043db8e534799957ece4979705a3d schema:name doi
133 schema:value 10.1007/s11060-022-04032-5
134 rdf:type schema:PropertyValue
135 Na1c2633be6194e5b91582e045720114e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Antineoplastic Combined Chemotherapy Protocols
137 rdf:type schema:DefinedTerm
138 Na5cf3d0e518f479db72ba48b9ef34949 schema:name pubmed_id
139 schema:value 35763119
140 rdf:type schema:PropertyValue
141 Naff6020c756d4583bd668371cf20e642 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Lymphopenia
143 rdf:type schema:DefinedTerm
144 Naff77926c0864d4bb3eb52fe48b14151 rdf:first sg:person.011205067533.95
145 rdf:rest N875e8948b90a4cdab63b06a6b934be9b
146 Ncaa18c385e21416d916ebe9e8cf26b45 schema:volumeNumber 159
147 rdf:type schema:PublicationVolume
148 Nd09df8550e13431f8366563c6609acc1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Central Nervous System
150 rdf:type schema:DefinedTerm
151 Nde5d32001242480aa9dc6e1478d13ea0 schema:name dimensions_id
152 schema:value pub.1149025622
153 rdf:type schema:PropertyValue
154 Nef284a43ce024433b226b5047a9022d2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Lymphocyte Count
156 rdf:type schema:DefinedTerm
157 Nf538ee9083264af7bf59b9314dad7fdf schema:issueNumber 1
158 rdf:type schema:PublicationIssue
159 Nfdf0a39a7918460e93819e227366f8d2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Lymphocyte Subsets
161 rdf:type schema:DefinedTerm
162 Nfff13cda59964747adca067c9edfbbc0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Rituximab
164 rdf:type schema:DefinedTerm
165 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
166 schema:name Medical and Health Sciences
167 rdf:type schema:DefinedTerm
168 anzsrc-for:1109 schema:inDefinedTermSet anzsrc-for:
169 schema:name Neurosciences
170 rdf:type schema:DefinedTerm
171 sg:journal.1094205 schema:issn 0167-594X
172 1573-7373
173 schema:name Journal of Neuro-Oncology
174 schema:publisher Springer Nature
175 rdf:type schema:Periodical
176 sg:person.01012432765.90 schema:affiliation grid-institutes:grid.411266.6
177 schema:familyName Barrié
178 schema:givenName Maryline
179 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01012432765.90
180 rdf:type schema:Person
181 sg:person.011205067533.95 schema:affiliation grid-institutes:grid.411266.6
182 schema:familyName Appay
183 schema:givenName Romain
184 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011205067533.95
185 rdf:type schema:Person
186 sg:person.01160514623.82 schema:affiliation grid-institutes:grid.411266.6
187 schema:familyName Tabouret
188 schema:givenName Emeline
189 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01160514623.82
190 rdf:type schema:Person
191 sg:person.013514371275.39 schema:affiliation grid-institutes:grid.411266.6
192 schema:familyName Berthelot
193 schema:givenName Axel
194 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013514371275.39
195 rdf:type schema:Person
196 sg:person.013546622047.13 schema:affiliation grid-institutes:grid.411266.6
197 schema:familyName Harlay
198 schema:givenName Vincent
199 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013546622047.13
200 rdf:type schema:Person
201 sg:person.01366075341.14 schema:affiliation grid-institutes:grid.411266.6
202 schema:familyName Bequet
203 schema:givenName Celine
204 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01366075341.14
205 rdf:type schema:Person
206 sg:person.0646537516.22 schema:affiliation grid-institutes:grid.411266.6
207 schema:familyName Campello
208 schema:givenName Chantal
209 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0646537516.22
210 rdf:type schema:Person
211 sg:person.0704465355.32 schema:affiliation grid-institutes:grid.464051.2
212 schema:familyName Chinot
213 schema:givenName Olivier
214 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0704465355.32
215 rdf:type schema:Person
216 sg:person.0721565704.73 schema:affiliation grid-institutes:grid.411266.6
217 schema:familyName Petrirena
218 schema:givenName Gregorio
219 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0721565704.73
220 rdf:type schema:Person
221 sg:pub.10.1007/s00262-020-02575-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1127141873
222 https://doi.org/10.1007/s00262-020-02575-y
223 rdf:type schema:CreativeWork
224 sg:pub.10.1007/s00277-021-04474-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1135850698
225 https://doi.org/10.1007/s00277-021-04474-3
226 rdf:type schema:CreativeWork
227 sg:pub.10.1007/s11060-007-9397-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052553767
228 https://doi.org/10.1007/s11060-007-9397-0
229 rdf:type schema:CreativeWork
230 grid-institutes:grid.411266.6 schema:alternateName APHM, CHU Timone, Service de Neurooncologie, Marseille, France
231 APHM, CHU Timone, Service d’anatomopathologie, Marseille, France
232 Neuro-Oncology Department, University Hospital La Timone, 264 rue Saint Pierre, 13005, Marseille, France
233 schema:name APHM, CHU Timone, Service de Neurooncologie, Marseille, France
234 APHM, CHU Timone, Service d’anatomopathologie, Marseille, France
235 Aix-Marseille Univ, CNRS, INP, Inst Neurophysiopathol, Marseille, France
236 Neuro-Oncology Department, University Hospital La Timone, 264 rue Saint Pierre, 13005, Marseille, France
237 rdf:type schema:Organization
238 grid-institutes:grid.464051.2 schema:alternateName Aix-Marseille Univ, CNRS, INP, Inst Neurophysiopathol, Marseille, France
239 schema:name APHM, CHU Timone, Service de Neurooncologie, Marseille, France
240 Aix-Marseille Univ, CNRS, INP, Inst Neurophysiopathol, Marseille, France
241 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...